AMicale des COXiens

Forum des actionnaires particuliers de NicOx
AccueilAccueil  GalerieGalerie  S'enregistrerS'enregistrer  ConnexionConnexion  

Partagez | 

 New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan

Aller en bas 
D@n (Daniel Beldio)


Nombre de messages : 3210
Age : 66
Localisation : Pays de l'Arbre et de l'Eau
Date d'inscription : 09/02/2007

MessageSujet: New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan   Ven 4 Fév - 13:25

Il s'agit de Pfizer et Takeda !...
A une époque, Takeda avait été évoqué comme partenaire potentiel de NicOx...

February 03, 2011 09:00 PM Eastern Time
New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan

YORK--(BUSINESS WIRE)--Pfizer Japan Inc. (“Pfizer,” headquarters:
Shibuya-ku, Tokyo) and Takeda Pharmaceutical Company Limited (“Takeda,”
headquarters: Chuo-ku, Tokyo) announced today an agreement to extend the
period for co-promotion in Japan for the rheumatoid arthritis (RA) drug
Enbrel® (generic name: etanercept). The companies also signed a new
co-promotion agreement in Japan for the investigational drug tofacitinib
(development code: CP-690,550), formerly known as tasocitinib, which is
being studied for multiple inflammatory conditions, including
rheumatoid arthritis. The co-promotion agreement between Takeda and
Pfizer for Tofacitinib is for RA and certain other potential indications
in Japan. Pfizer will receive a milestone payment from Takeda at the
launch of Tofacitinib and Takeda will receive a percentage of sales
(based on certain conditions specified in the contract) as a
co-promotion fee from Pfizer. Contractual details are not disclosed.

“We are looking forward to the next phase of our successful partnership with Takeda”

are looking forward to the next phase of our successful partnership
with Takeda,” said Michael Goettler, regional president of Asia-Pacific
and Japan Head, Specialty Care Business Unit, Pfizer. “We are proud of
our current inflammation product portfolio, and excited about the
prospect of bringing new innovative treatments to our patients.”

binds with tumor necrosis factor alpha (TNF alpha - a cytokine*),
inhibiting its activity, and with lymphotoxin alpha (another cytokine),
and reduces RA inflammation. The drug is currently approved in over 80
countries worldwide and is used by over 600,000 patients, including
patients using the drug for indications other than RA.

is a novel, oral Janus kinase (JAK)** inhibitor that is being
investigated as a targeted immunomodulator in RA, psoriasis and other
indications. Unlike current therapies for RA, tofacitinib takes a novel
approach, targeting the intracellular signaling pathways that operate as
hubs in the inflammatory cytokine network. Currently, in Japan, Pfizer
is carrying out Phase 3 clinical trials of the investigational drug for
RA and, in other countries, the company is also studying tofacitinib in
psoriasis, Crohn’s disease and ulcerative colitis.

“With these
new contracts, we will be able to further strengthen our initiatives in
the rheumatoid arthritis field,” said Yasuhiko Yamanaka, a member of the
board, senior vice president, Pharmaceutical Marketing Division of
Takeda. “Takeda and Pfizer together provide Enbrel to patients suffering
from RA, and if the development program is successful, we look forward
to offering a new treatment option. We are committed to further
contribution to treatments for RA therapy."

* A generic name for
proteins which are released from cells and mediate cell-cell
interactions. They play a key role in immunity, inflammation and
biological defense.

** Tyrosine kinase is related to autoimmune
diseases, such as RA, and plays a key role in signaling related to cell
growth and differentiation (tyrosine kinase: an enzyme which adds
phosphoric acid to tyrosine, one of amino acids that make up proteins)

About Pfizer Japan

Japan Inc. has been working for a healthier world by providing
pharmaceutical and animal health products since our establishment in
1953. We provide drugs that cover a wide range of disease categories,
including cardiovascular, inflammation, central nervous system,
infectious disease, urology, ophthalmology, oncology, endocrinology and
vaccine etc. For further information, please visit us at

About Takeda

in Osaka, Japan, Takeda is a research-based global company with its
main focus on pharmaceuticals. As the largest pharmaceutical company in
Japan and one of the global leaders of the industry, Takeda is committed
to strive towards better health for patients worldwide through leading
innovation in medicine. Additional information about Takeda is available
through its corporate website,

Pfizer Inc.: Working together for a healthier world™

Pfizer, we apply science and our global resources to improve health and
well-being at every stage of life. We strive to set the standard for
quality, safety and value in the discovery, development and
manufacturing of medicines for people and animals. Our diversified
global health care portfolio includes human and animal biologic and
small molecule medicines and vaccines, as well as nutritional products
and many of the world’s best-known consumer products. Every day, Pfizer
colleagues work across developed and emerging markets to advance
wellness, prevention, treatments and cures that challenge the most
feared diseases of our time. Consistent with our responsibility as the
world’s leading biopharmaceutical company, we also collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, Pfizer has worked to make a difference for all who
rely on us. To learn more about our commitments, please visit us at

DISCLOSURE NOTICE: The information contained in this release is as of
February 3, 2011. Pfizer assumes no obligation to update forward-looking
statements contained in this release as the result of new information
or future events or developments.

This release contains
forward-looking information about new co-promotion agreements and a
product in development, tofacitinib, including their potential benefits,
that involves substantial risks and uncertainties. Such risks and
uncertainties include, among other things, the uncertainties inherent in
research and development; decisions by regulatory authorities regarding
whether and when to approve any drug applications that may be filed for
tofacitinib as well as their decisions regarding labeling and other
matters that could affect its availability or commercial potential; and
competitive developments.

A further description of risks and
uncertainties can be found in Pfizer’s Annual Report on Form 10-K for
the fiscal year ended December 31, 2009 and in its reports on Form 10-Q
and Form 8-K.


Pfizer Japan Inc.
Communications, Specialty Care Business Unit
Pfizer Media:
Gwendolyn E. Fisher
Pfizer Investor:
Jennifer M. Davis
Takeda Pharmaceutical Company Limited
Corporate Communications

Revenir en haut Aller en bas
Voir le profil de l'utilisateur

Nombre de messages : 272
Age : 60
Localisation : 29
Date d'inscription : 02/06/2008

MessageSujet: Re: New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan   Ven 4 Fév - 20:10

Tu en déduis quoi ?
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan
Revenir en haut 
Page 1 sur 1

Permission de ce forum:Vous ne pouvez pas répondre aux sujets dans ce forum
AMicale des COXiens :: Forum public :: Echanges sur NicOx-
Sauter vers: